N. Mederos-Alfonso

Most-cited papers

1. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.

   E. Ghisoni, A. Wicky, H. Bouchaab, M. Imbimbo +21 more

   2021European Journal of Cancer188 citations Open access

   Semantic Scholar

   Save

2. Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.

   A. M. da Silva Lopes, S. Colomer-Lahiguera, N. Mederos-Alfonso, V. Aedo-Lopez +11 more

   2021European Journal of Cancer20 citations Open access

   Semantic Scholar

   Save

3. Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

   Matthias Guckenberger, I. Opitz, T. Dellaporta, Alessandra Curioni-Fontecedro +21 more

   2025Lung Cancer11 citations Open access

   Semantic Scholar

   Save

4. Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor–Related Myocarditis

   D. Daoudlarian, S. Boughdad, R. Bartolini, S. Latifyan +17 more

   2026JACC CardioOncology4 citations Open access

   Semantic Scholar

   Save

5. Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.

   E. Ghisoni, A. Wicky, S. Latifyan, N. Mederos-Alfonso +16 more

   20202 citations

   Semantic Scholar

   Save

6. EP12.53: Addition of Chemotherapy to Targeted Therapy at Progression in RET- and ROS1-Rearranged NSCLC: Insights From a Case Series and Therapeutic Implications

   N. Mederos-Alfonso, V. Mosimann, N. Ferahta, M. Meyer +6 more

   2026Journal of Thoracic Oncology0 citations

   Semantic Scholar

   Save

7. EP.09.17 Permanent Local Control After Orbital Cryoablation for Ocular Metastasis From Lung Cancer

   N. Mederos-Alfonso, T. Nguyenngoc, M. Christofis, A. Serena +8 more

   2025Journal of Thoracic Oncology0 citations Open access

   Semantic Scholar

   Save

8. EP08.01-069 A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs

   N. Mederos-Alfonso

   2022Journal of Thoracic Oncology0 citations Open access

   Semantic Scholar

   Save

9. 153P Safety profile and associated costs of therapies for relapsed small cell lung cancer in Switzerland

   M. Jörger, B. G. Andrés, M. Joerger, N. Mederos-Alfonso +2 more

   2022Annals of Oncology0 citations Open access

   Semantic Scholar

   Save

10. 1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study

    A. Lopes, S. Colomer‐Lahiguera, N. Mederos-Alfonso, V. A. Lopez +11 more

    2021Annals of Oncology0 citations Open access

    Semantic Scholar

    Save